Rapid responses, few adverse effects in targeted agent in Phase1 trial in rare blood disorder

(Dana-Farber Cancer Institute) Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis. Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news